^
    Back
    Association details:
    Biomarker:TNFRSF8 positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug Class:T-lymphocyte cell therapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2022
    Title:

    164 Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30+ T-Cell Lymphoma: Clinical and Biological Studies

    Published date:
    11/03/2022
    Excerpt:
    We conducted a phase 1 dose-escalation study in 11 patients with R/R HL or CD30+ T-NHL….Our Phase 1 study provides evidence for feasibility and safety of HSP-CAR30. Additionally, HSP-CAR30 has shown promising efficacy in heavily treated cHL patient population, and this is being explored in the phase 2.
    DOI:
    https://doi.org/10.1182/blood-2022-167504
    Trial ID:
    NCT04653649